Literature DB >> 20496549

Cholangiocarcinoma: risk factors and clinical presentation.

M Gatto1, D Alvaro.   

Abstract

Cholangiocarcinoma (CCA), a cancer originating from the neoplastic transformation of the biliary epithelium, is characterized by a progressive increase in incidence and prevalence. A number of risk factors have been identified including primary sclerosing cholangitis, liver fluke infestation, and hepatolithiasis. More recently, hepatitis viruses (HCV, HBV) have been taken into consideration as risk factors for the intrahepatic CCA and this could explain the increased incidence seen in the last two decades. All these risk factors induce chronic inflammation in the biliary epithelium together with partial bile obstruction. These two conditions are considered the background (chronic inflammation) favouring the cancer development. The only effective treatment is the radical surgical resection but, this is applicable in less than 40% of the patients since CCA is mostly diagnosed at an advanced stage. This mainly occurs because, in the majority of the cases, CCA is clinically silent, with symptoms only developing at an advanced stage but also for the lack of effective biomarkers to be used for a screening purpose. A number of serum and bile biomarkers have been recently proposed for the diagnosis of CCA but, their impact on the early diagnosis is still under the evaluation.

Entities:  

Mesh:

Year:  2010        PMID: 20496549

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

Review 2.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

Review 3.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

4.  Effect of p38 mitogen-activate protein kinase on MUC5AC protein expression of bile duct epithelial cells in hepatolithiasis patients.

Authors:  Ping Wang; Xiaodong Ma; Yu He; Beiwang Sun; Canhua Zhu; Rujin Zhao; Shaoling Zhang; Xianxian Huang; Yanmin Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  Macrophage density and macrophage colony-stimulating factor expression predict the postoperative prognosis in patients with intrahepatic cholangiocarcinoma.

Authors:  Kosuke Oishi; Takanori Sakaguchi; Satoshi Baba; Shohachi Suzuki; Hiroyuki Konno
Journal:  Surg Today       Date:  2014-07-23       Impact factor: 2.549

Review 6.  Hepatitis B virus infection and intrahepatic cholangiocarcinoma.

Authors:  Hua-Bang Zhou; Jing-Yi Hu; He-Ping Hu
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

7.  Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells.

Authors:  Chutamas Thepmalee; Aussara Panya; Jatuporn Sujjitjoon; Nunghathai Sawasdee; Naravat Poungvarin; Mutita Junking; Pa-Thai Yenchitsomanus
Journal:  Hum Vaccin Immunother       Date:  2020-01-24       Impact factor: 3.452

8.  Digital lesion leading to diagnosis of cholangiocarcinoma.

Authors:  Dhauna Karam; Bharat Agrawal; Chandra Mouli
Journal:  BMJ Case Rep       Date:  2017-10-04

9.  Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling.

Authors:  Christopher Johnson; Victoria Huynh; Laura Hargrove; Lindsey Kennedy; Allyson Graf-Eaton; Jennifer Owens; Jerome P Trzeciakowski; Kyle Hodges; Sharon DeMorrow; Yuyan Han; Lucas Wong; Gianfranco Alpini; Heather Francis
Journal:  Am J Pathol       Date:  2015-11-18       Impact factor: 4.307

10.  Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma.

Authors:  Renumathy Dhanasekaran; Alan W Hemming; Ivan Zendejas; Thomas George; David R Nelson; Consuelo Soldevila-Pico; Roberto J Firpi; Giuseppe Morelli; Virginia Clark; Roniel Cabrera
Journal:  Oncol Rep       Date:  2013-02-18       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.